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a  b  s  t  r  a  c  t
To  determine  the age  at which  infants  mount  signiﬁcant  neutralising  antibody  responses  to  both  natural
RSV  infection  and  live  vaccines  that  mimic  natural  infection,  RSV-speciﬁc  neutralising  antibodies  in the
acute  and  convalescent  phase  sera  of infants  with  RSV  infection  were  assayed.  Age-speciﬁc  incidence
estimates  for  hospitalisation  with  severe  RSV  disease  were  determined  and  compared  to age-speciﬁc
neutralising  antibody  response  patterns.  Disease  incidence  peaked  at between  2 and  3.9  months  of  life.eywords:
espiratory syncytial virus
eutralising antibody
mmunity
Following  natural  infection,  relative  to the mean  acute  phase  antibody  titre,  the mean  convalescent  titre
was  lower  in  the 0–1.9  month  age  class,  no  different  in  the 2–3.9 month  age  class  and greater  in all  age
classes  greater  than  4 months.  These  data  suggest  effective  vaccination  with  live vaccines  that  mimic
natural  infection  may  not  be achieved  before  the  age  of 4 months.  Maternal  vaccination  may  be an
alternative  to  direct  infant  vaccination  in  order  to protect  very  young  babies.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
RSV is an important cause of acute lower respiratory infection
n infants and elderly adults [1]. Recent estimates have shown the
onsiderable global burden of RSV-associated disease [2] and have
ighlighted the need for the development of effective vaccines for
se in vulnerable populations. Severe RSV infection in infants can
esult in the development of potentially life-threatening severe
neumonia [3] and is increasingly being recognised as predisposing
o severe pneumonia in the short term [4] and as a risk factor for
he development of wheeze and asthma in later life [5]. Previous
tudies have provided evidence that immunity from lower respira-
ory tract disease correlates with levels of neutralising antibodies
6,7], an assertion that is supported by the clinical experience with
he prophylactic neutralising monoclonal antibody, Palivizumab,
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which has been associated with up to a 78% reduced risk of hospi-
talisation among premature infants [8].
The key target group for vaccination against RSV is infants
under the age of 6 months in whom the risk of severe disease
is greatest. The prospect of active immunisation of this popula-
tion is hindered by safety concerns related to the administration
of non-replicating vaccines which are associated with potentiation
of disease upon re-exposure in both infants [9] and animals [10].
In contrast, replicating vaccines such as live-attenuated vaccines
have been shown in several clinical trials to have a relatively good
safety proﬁle [11,12] and are thought to be the safest alternative
for providing direct protection for infants. RSV vaccine develop-
ment faces the additional challenge of vaccinating infants at an age
that is associated with both a high prevalence of maternally derived
antibodies as well as relative immunological immaturity. The asso-
ciation between age and the neutralising response to natural RSV
infection in infants is therefore an important consideration in the
development of live-attenuated vaccines, whose antigenic proﬁle
is thought to closely mirror that of wild type virus and which might
therefore be expected to induce responses that broadly resemble
natural infection responses. This study investigated the develop-
ment of neutralising antibody responses generated upon natural
infection in early infancy. The implications of the results on infant
vaccination strategy are discussed.
nder the CC BY-NC-ND license
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Fig. 1. (a) The relationship between acute and convalescent phase titres with age. Mean acute phase titres are depicted by the black ﬁlled boxes (with corresponding 95%
conﬁdence intervals) while mean convalescent phase titres are shown in grey ﬁlled boxes (with 95% conﬁdence intervals). The p values above each mean acute/convalescent
pair  indicate whether the mean differences in titre are statistically signiﬁcant. The values below the acute/convalescent pair are the number of individuals in each age class
whose acute/convalescent responses were analysed. (b) Comparison between age-speciﬁc incidence estimates of admission with severe disease and the ability to generate a
neutralising antibody response following natural infection. The incidence of admission with RSV associated pneumonia within the Kiliﬁ Health and Demographic Surveillance
System (with corresponding 95% conﬁdence intervals) is shown in the grey bars while the mean fold change in neutralising antibody titre from the acute to convalescent
phases  of infection are depicted using the black ﬁlled boxes (with corresponding 95% conﬁdence intervals). The horizontal dashed line indicates a 1-fold change in titre;
above  which a rise in titre is observed and below which a decline in titre is observed. The solid horizontal line indicates the 4-fold level that is used to deﬁne a seroconversion.
The  p values against the vertical dashed lines connecting the mean fold changes in titre to the horizontal dashed line indicating a 1-fold change in titre indicate whether the
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. Materials and methods
The study was set in the Kiliﬁ District Hospital (KDH) on
he coast of Kenya [14]. Acute and convalescent phase sera, col-
ected at admission and approximately 4 weeks after admission,
espectively, were obtained from 99 patients aged 6 days to 41
onths who were admitted to KDH with severe RSV infection.
SV diagnosis was done using an immunoﬂuorescent antibody
est on nasopharyngeal samples [13]. Neutralising antibodies to
he A2 strain of RSV were measured by a previously described
icroplaque reduction neutralisation assay [15]. Written informed
onsent was sought from children’s parents while ethical approval
or the study was granted by the Kenya Medical Research Institute
thical Review Committee.
Data were analysed using Stata (StataCorp, Texas). For the esti-
ation of both disease incidence and antibody response, data were
tratiﬁed in ﬁve age classes: 0–1.9, 2–3.9, 4–5.9, 6–11.9 and 12–41.9
onths of age. Age-speciﬁc incidence estimates for admission with
evere RSV pneumonia were calculated for the period January 1st
002 to December 31st 2008, by dividing the number of pneumo-
ia admissions resident in KHDSS with a laboratory diagnosis of
SV by the resident population size at the midpoint of the study
eriod [13]. The difference between the mean acute and convales-
ent phase titres in different age classes was tested using a paired t
est. To determine whether a signiﬁcant response to infection was
enerated following infection, the magnitude of the neutralising
ntibody response – expressed as fold change in titre from the acute
o convalescent phases of infection – was compared to a value of 1
sing an unpaired t test.between age-speciﬁc incidence estimates of disease and fold changes in titre from
3. Results
In the ﬁrst year of life there was  a progressive decline in the
titre of acute phase neutralising antibodies, which coincided with
an increase in convalescent titres over the same period (Fig. 1a).
The incidence of severe RSV associated pneumonia during the study
period rose sharply after birth; starting at 1108 admissions/100,000
child years of observation (cyo) at between 0 and 1.9 months of
age (95% CI: 906–1310) and peaking at 1378 admission/100,000
cyo (95% CI: 1140–1616) at between 2 and 3.9 months of age.
The incidence of severe RSV pneumonia thereafter declined to 934
admissions/100,000 cyo (95% CI: 740–1128) in the 4–5.9 month
age class, and was lowest in the 6–11.9 and 12–41.9 month age
classes at 499 admissions/100,000 cyo (95% CI: 420–578) and 56
admissions/100,000 cyo (95% CI: 46–65), respectively, as shown in
Fig. 1b. In the ﬁrst year of life the response to infection, measured
as fold change in neutralising antibody titre from the acute to con-
valescent phases of infection, increased progressively with age. In
the ﬁrst 2 months of life (0–1.9 months), there was a signiﬁcant
decline in the neutralising response, i.e.,  fold change less than unity
(p = 0.02; Fig. 1), while no signiﬁcant change in titre was  observed
at 2–3.9 months of age (p = 0.1). However, as shown in Fig. 1b, in all
age classes of children older than 4 months of age, there was a sig-
niﬁcant rise in the titre of neutralising antibodies following natural
infection.The proportion of infants who  had a detectable rise in titre from
the acute to convalescent phases of infection (fold change in titre
>1) increased with age as shown in Fig. 2. In the youngest age
class (0–1.9 months old), only 26% of infants with a conﬁrmed RSV
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Fig. 2. The increase in the magnitude of the neutralising antibody response with age. The percentage of all infants within speciﬁc age classes with any rise in titre (**) and
the  proportion of infants who seroconverted (*) following natural infection is shown. The vertical lines indicate the fold change in titre from the acute to convalescent phases
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nfection had a rise in titre following infection. In subsequent age
lasses, the proportion of infants with a detectable rise in the titre of
eutralising antibodies following infection rose sharply with age,
eaching 66% in the 2–3.9 month age class and 60% in the 4–5.9
onth age class. The greatest response was observed in the 6–11.9
onth age class where all infants had detectable rises in titre fol-
owing infection. The same trend was observed when the data were
nalysed in terms of infants who generated an antibody response
hat reached or exceeded the 4-fold seroconversion threshold. No
eroconversions were observed in the youngest age class (0–1.9
onths old). However in subsequent age classes the rate of sero-
onversion steadily increased with age. Seroconversion rates in the
–3.9, 4–5.9, 6–11.9 and 12–41.9 months of age were 11%, 33%, 62%
nd 50% respectively.
. Discussion
In the current study, age-speciﬁc neutralising antibody response
atterns to natural infection were determined among infants of
ifferent ages in order to provide an accurate estimate of the
oungest age at which infants mount robust neutralising antibody
esponses. In contrast to the signiﬁcant increases in the neutralis-
ng response observed among infants who were above 4 months
f age, there was, a signiﬁcant decline in the neutralising anti-
ody response in the 0–2.9 month age class, while in the 2–3.9
onth age class, where disease burden was greatest, there was
o signiﬁcant change in titre following infection. Previous work
as suggested that infants under the age of 6 months, generally
ount poor responses to infection [16], an effect that is not linked
o age per se,  but rather to the titre of pre-existing antibodies at
he time of infection [17]. This poor responsiveness is postulated
o be due to suppressive effects of maternally derived antibodies
y mechanisms such as epitope masking and Fc receptor mediated
hagocytosis of antibody–virus complexes [18]. The data presented
ere suggest that as a result of passive maternal antibody decline,
hese suppressive effects are sufﬁciently diminished by around
 months of age, to allow for the detection of signiﬁcant infant
esponses to infection. The responses presented in this paper are
resumed to be representative of the general infant population who
redominantly suffer mild disease. Similar studies in infants with
ild disease should be the subject of future research in order tober of individuals in that age class. Responses greater than unity indicate rises in
quivalent to or greater than a 4-fold rise in titre (dashed line) are considered to be
establish the validity of this extrapolation. The disease incidence
estimates presented in Fig. 1b, suggest that in order to have the
greatest impact on disease burden, infants should be vaccinated
prior to the period of greatest risk of disease, at about 2 months
of age. However the poor response to natural infection in infants
under the age of 4 months suggests that such infants are unlikely
to mount strong neutralising antibody responses to live vaccines.
Nonetheless, the data presented suggest that vaccination of infants
aged 4 months and above is likely to provide substantial beneﬁt.
To protect very early infants at the period of greatest risk, there is
need to explore alternative strategies such as maternal vaccination.
The boosting of the titre of trans-placentally transferred antibody
will increase the duration of infant protection and delay the age
of ﬁrst infection, at which time infection is less likely to result in
severe disease [19]. Recent studies [20,21] show that some vac-
cines that are designed for maternal vaccination are both protective
in animals and have a good safety and immunogenicity proﬁle in
healthy adults, providing some basis to suggest that this might be
a viable alternative to the direct vaccination of the young infant
or suit a combined strategy of maternal vaccination followed by
delayed later infant active immunisation.
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